VA to Conduct Large Randomized Trial to Study Impact of Myriad GeneSight Test in Depression

Nov 10, 2017

|

NEW YORK (GenomeWeb) – The US Department of Veterans Affairs has launched a large, randomized clinical trial to assess whether using Myriad Genetics' GeneSight pharmacogenetic test helps get patients with major depressive disorder to the right treatment and improves their outcomes.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

VA to Conduct Large Randomized Trial to Study Impact of Myriad GeneSight Test in Depression

To read the full story....

Breaking News

BARDA Awards $5.4M to Luminex for Expanded Respiratory Panel With Coronavirus Target

In Brief This Week: Thermo Fisher Scientific, Fluidigm, Veracyte, and More

Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

BGI Genomics Gets CE Mark for Multiplexed SARS-CoV-2, Influenza Tests

Commercial Coronavirus Antibody Tests Show Wide Variation in Accuracy in New Study

Clear Labs Nanopore Sequencing Coronavirus Test Gets FDA Emergency Use Authorization

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

What's Popular?

United Airlines Launches COVID-19 Testing Program for Travelers to Hawaii

BioReference Settles False Claims, Kickback Allegations for $11.5M

FDA Grants Emergency Use Authorizations for Quadrant Biosciences, KimForest Coronavirus Tests

Vela Diagnostics Receives Second FDA Emergency Use Authorization for SARS-CoV-2 Molecular Test

FDA Revises Emergency Use Authorization for Abbott Point-of-Care SARS-CoV-2 Test

Sponsorships